Liminatus Pharma (LIMN) Stock Statistics & Valuation Metrics

Liminatus Pharma has a market cap or net worth of $140.48M. The enterprise value is $145.42M.

Liminatus Pharma has 26,014,633 shares outstanding. The number of shares has decreased by -2.65% in one year.

Liminatus Pharma’s return on equity (ROE) is <0.01 and return on invested capital (ROIC) is 2.64%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Liminatus Pharma had revenue of 0.00 and earned -405.00 in profits. Earnings per share was -4.05.

In the last 12 months, operating cash flow was -2.20M and capital expenditures -10.00, giving a free cash flow of -2.20M billion.

Liminatus Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Liminatus Pharma upcoming earnings date is ―, ―.

Liminatus Pharma as a current ratio of 0.09, with Debt / Equity ratio of 0.00%

In the past 12 months, Liminatus Pharma has paid 18.84K in taxes.

Liminatus Pharma EV to EBITDA ratio is -10.66K, with an EV/FCF ratio of -1.39.

Liminatus Pharma has $0.00 in cash and marketable securities with $0.00 in debt, giving a net cash position of $0.00 billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Liminatus Pharma is ―, which is 11.43% higher than the current price. The consensus rating is ―